ALTER — Theradiag SA Share News
0.000.00%
Last trade - 00:00- €16.44m
- €12.36m
- €12.20m
Brief: Theradiag Signs Partnership Agreement With MSD France To Supply Its Lisa Tracker Kits
Brief: Theradiag Provides Update On Prestizia And Its Partnership With HOB Biotech
Brief: Theradiag 9-month revenue rises to 6.8 million euros
Brief: Theradiag H1 operating loss narrows to 0.9 million euros
Brief: Theradiag H1 revenue rises to 5.0 million euros
Brief: Theradiag announces free allocation of BSARs
Brief: Theradiag successful capital increase raising 4 million euros
Brief: Theradiag announces the launch of a capital increase
Brief: Theradiag Q1 revenue stable at 2.3 million euros
Brief: Theradiag FY net loss narrows to eur 2.1 million euros
Brief: Theradiag receives support for its development of microRNA biomarkers in oncology from Eurostars-Eureka Program
Brief: Theradiag 9 months revenue of 6.4 million euros, up 31%
Brief: Theradiag carries out a capital increase fully subscribed by its Chinese partner HOB Biotech
Brief: Theradiag H1 revenue up 36 pct at 4.6 million euros
Brief: Lisa Tracker chosen to monitor patients treated with Remicade in the US
Brief: Theradiag Q2 revenues rise 12 percent to 2.4 million euros
Brief: Theradiag says Lisa tracker launched in the us market
Brief: Theradiag Q1 revenue up 50 percent at 2.2 million euros
Brief: Theradiag to present results at JFHOD congress